NYSE:HAE - Haemonetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $106.59 -1.92 (-1.77 %) (As of 10/19/2018 04:00 PM ET)Previous Close$108.51Today's Range$105.96 - $109.6052-Week Range$44.90 - $117.56Volume21,064 shsAverage Volume473,545 shsMarket Capitalization$5.72 billionP/E Ratio57.72Dividend YieldN/ABeta1.02 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts. Receive HAE News and Ratings via Email Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical SymbolNYSE:HAE CUSIP40502410 Webwww.haemonetics.com Phone781-848-7100 Debt Debt-to-Equity Ratio0.49 Current Ratio2.84 Quick Ratio1.94 Price-To-Earnings Trailing P/E Ratio57.72 Forward P/E Ratio46.75 P/E Growth3.59 Sales & Book Value Annual Sales$903.92 million Price / Sales6.10 Cash Flow$3.4131 per share Price / Cash31.23 Book Value$14.08 per share Price / Book7.57 Profitability EPS (Most Recent Fiscal Year)$1.87 Net Income$45.57 million Net Margins2.45% Return on Equity15.00% Return on Assets9.04% Miscellaneous Employees3,136 Outstanding Shares51,690,000Market Cap$5.72 billion Haemonetics (NYSE:HAE) Frequently Asked Questions What is Haemonetics' stock symbol? Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE." How will Haemonetics' stock buyback program work? Haemonetics announced that its board has approved a stock repurchase program on Tuesday, February 6th 2018, which authorizes the company to buyback $260,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Tuesday, August, 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.17. The medical instruments supplier had revenue of $229.35 million for the quarter, compared to analyst estimates of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. View Haemonetics' Earnings History. When is Haemonetics' next earnings date? Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Haemonetics. How can I listen to Haemonetics' earnings call? Haemonetics will be holding an earnings conference call on Tuesday, November 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8778488880. What guidance has Haemonetics issued on next quarter's earnings? Haemonetics issued an update on its FY19 earnings guidance on Tuesday, August, 7th. The company provided earnings per share guidance of $2.00 to $2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.17. The company issued revenue guidance of $931.04 million to $949.12 million, compared to the consensus revenue estimate of $944.25 million. What price target have analysts set for HAE? 6 analysts have issued 1 year target prices for Haemonetics' stock. Their forecasts range from $50.00 to $127.00. On average, they anticipate Haemonetics' stock price to reach $98.80 in the next year. This suggests that the stock has a possible downside of 7.0%. View Analyst Price Targets for Haemonetics. What is the consensus analysts' recommendation for Haemonetics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics. What are Wall Street analysts saying about Haemonetics stock? Here are some recent quotes from research analysts about Haemonetics stock: 1. According to Zacks Investment Research, "Over the past year, Haemonetics has been outperforming its industry. The company has been delivering encouraging performance banking on solid execution of its multi-year turnaround strategy. Continued momentum in new business generation and geographical expansion has helped drive results. The company also seems to be upbeat about the receipt of some major regulatory clearances for the Plasma business. Moreover, a strong cash position boosts investors’ confidence. However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segments, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (10/12/2018) 2. Barrington Research analysts commented, "We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus)." (10/5/2018) 3. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018) Who are some of Haemonetics' key competitors? Some companies that are related to Haemonetics include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Integra Lifesciences (IART), Penumbra (PEN), Novocure (NVCR), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA) and Glaukos (GKOS). Who are Haemonetics' key executives? Haemonetics' management team includes the folowing people: Mr. Christopher Simon, CEO, Pres & Director (Age 54)Mr. William P. Burke, CFO & Exec. VPMs. Michelle L. Basil, EVP, Gen. Counsel & Sec.Ms. Jacqueline Scanlan, Sr. VP of Global HRMr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41) Who are Haemonetics' major shareholders? Haemonetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.94%), Copper Rock Capital Partners LLC (0.55%), Nisa Investment Advisors LLC (0.04%), Aperio Group LLC (0.03%), Seven Eight Capital LP (0.02%) and Bowling Portfolio Management LLC (0.02%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics. Which institutional investors are selling Haemonetics stock? HAE stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Seven Eight Capital LP, Bowling Portfolio Management LLC, Bank of Montreal Can and CAPROCK Group Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Insider Buying and Selling for Haemonetics. Which institutional investors are buying Haemonetics stock? HAE stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Nisa Investment Advisors LLC, Aperio Group LLC, State of Alaska Department of Revenue, Oakbrook Investments LLC and Welch & Forbes LLC. View Insider Buying and Selling for Haemonetics. How do I buy shares of Haemonetics? Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Haemonetics' stock price today? One share of HAE stock can currently be purchased for approximately $106.28. How big of a company is Haemonetics? Haemonetics has a market capitalization of $5.72 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,136 workers across the globe. What is Haemonetics' official website? The official website for Haemonetics is http://www.haemonetics.com. How can I contact Haemonetics? Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected] MarketBeat Community Rating for Haemonetics (NYSE HAE)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 322 (Vote Underperform)Total Votes: 554MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/19/2018 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?